Lepelletier D, Lucet J C, Astagneau P, Coignard B, Vaux S, Rabaud C, Grandbastien B, Berthelot P
Bacteriology and Infection Control Department, Nantes University Hospital, 44093, Nantes, France,
Eur J Clin Microbiol Infect Dis. 2015 Aug;34(8):1615-20. doi: 10.1007/s10096-015-2396-8. Epub 2015 May 10.
We performed a multicenter survey in May-June 2012 to assess strategies in preventing the spread of emerging extensively drug-resistant organisms (eXDRO), including glycopeptide-resistant enterococci and carbapenemase-producing Enterobacteriaceae, in a convenient sample of French healthcare facilities (HCFs). The collected data included organization and measures to: (1) identify patients at risk for carrying eXDRO, (2) investigate and control sporadic cases or outbreaks, and (3) describe prior 2010-2012 episodes with one or more colonized patients. Of the 286 participating HCFs, 163 (57 %) and 134 (47 %) reported having a specific procedure to detect repatriates or patients hospitalized in foreign countries within the last year, respectively. Among the 97 HCFs with prior at-risk patient management experience, contact precautions, hospitalization in a single room, and screening for eXDRO carriage were quasi-systematically performed (n = 92/97, 95 %). The alleged time between admission and alert ranged from 24 to 48 h after the patient's admission; 203 (71 %) HCFs recommended obtaining three successive negative screening samples to declare a patient free of eXDRO colonization. During the last two years, 64 HCFs (23 %) had to manage at least one eXDRO case, with a total of 20 outbreaks with more than one secondary case. This first national survey shows that French HCFs were not totally ready to control eXDRO spread in 2012. Their previous experiences and capacities in controlling eXDRO outbreaks are quite heterogeneous from one hospital to another. Further researches are needed in order to understand the constraints in applying national guidance.
2012年5月至6月,我们开展了一项多中心调查,以评估法国医疗机构便利样本中预防新出现的广泛耐药菌(eXDRO,包括耐糖肽肠球菌和产碳青霉烯酶肠杆菌科细菌)传播的策略。收集的数据包括以下方面的组织和措施:(1)识别携带eXDRO的高危患者;(2)调查和控制散发病例或暴发疫情;(3)描述2010 - 2012年期间有一名或多名定植患者的既往事件。在286家参与调查的医疗机构中,分别有163家(57%)和134家(47%)报告称有特定程序来检测归国人员或过去一年内在国外住院的患者。在97家有既往高危患者管理经验的医疗机构中,接触预防措施、单间住院以及eXDRO携带情况筛查几乎是系统性实施的(n = 92/97,95%)。据称,从患者入院到发出警报的时间间隔为入院后24至48小时;203家(71%)医疗机构建议获取连续三份阴性筛查样本以宣布患者未感染eXDRO。在过去两年中,64家(23%)医疗机构至少处理过一例eXDRO病例,共有20起暴发疫情,且有不止一例二代病例。这项首次全国性调查表明,法国医疗机构在2012年并未完全准备好控制eXDRO的传播。它们在控制eXDRO暴发方面的既往经验和能力在不同医院之间差异很大。需要进一步开展研究以了解在应用国家指南时所面临的制约因素。